^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

calotatug ginistinag (XMT-2056)

i
Other names: XMT-2056, XMT 2056, XMT2056
Company:
GSK, Mersana
Drug class:
HER2-targeted antibody-drug conjugate, STING agonist
Related drugs:
9ms
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 (clinicaltrials.gov)
P1, N=162, Recruiting, Mersana Therapeutics | Suspended --> Recruiting | Trial completion date: Nov 2025 --> Apr 2027 | Trial primary completion date: Nov 2025 --> Apr 2027
Enrollment open • Trial completion date • Trial primary completion date • Metastases
|
HER-2 amplification • HER-2 mutation • HER-2 expression
|
calotatug ginistinag (XMT-2056)
over2years
XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab (AACR 2022)
To this end, administration of an XMT-2056 surrogate ADC in combination with an anti-PD1 agent improved anti-tumor activity in a ratHER2-engineered EMT-6 syngeneic mouse model. Together these data support the potential of XMT-2056 both as a monotherapy and in combination with other HER2 targeted agents as well as checkpoint inhibitors.
Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2 underexpression
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • calotatug ginistinag (XMT-2056)